Advisory Board

Dr. Antoaneta Vladimirova

Antoaneta Vladimirova, Ph.D., M.Sc. is currently Director, Medical AI, at Roche DIS.
Antoaneta was previously in Product Management lead roles at Roche DIS, and Director, Scientific Applications, Partnerships & Product Strategy at Station X (acquired by Roche), Director, Scientific Liaison at NextBio (acquired by Illumina), Scientific Manager & Program Manager at Ingenuity Systems (acquired by Qiagen), and Principal Scientist at Iconix Biosciences (acquired by Entelos).
She coauthored Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities, Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action, Pathway analysis tools and toxicogenomics reference databases for risk assessment, Key Aspects of Toxicogenomic Data Analysis and Interpretation as a Safety Assessment Tool to Identify and Understand Drug-Induced Toxicity, and In Silico Approaches Inform Drug Repurposing Strategies for the Treatment of Ebola Infection.
Antoaneta earned her M.Sc. in Biotechnology and Genetic Engineering at Sofia University St. Kliment Ohridski, Bulgaria in 1991. She earned her Ph.D. in Molecular and Cell Biology at New York University in 1999 and earned her M.Sc. in Computer Science at the New Jersey Institute of Technology in 2003.
Visit her Facebook page.